PDS Biotech refocuses on PDS0301, seeks PDS0101 partnerships
PDS Biotech will concentrate resources on PDS0301 and pursue external funding for PDS0101, signaling disciplined capital allocation. Positive Phase 2 mCRC signals—71% ORR at 6 months and 80% 24-month survival—underpin the pivot, while the company aims to finalize Phase 2b development within 18–24 months and pursue strategic partnerships for PDS0101.
View signal analysis